NASDAQ:EDIT Editas Medicine (EDIT) Stock Forecast, Price & News $6.92 -0.19 (-2.67%) (As of 09/28/2023 ET) Add Compare Share Share Today's Range$6.84▼$7.0550-Day Range$6.92▼$9.3152-Week Range$6.33▼$14.23Volume1.21 million shsAverage Volume1.81 million shsMarket Capitalization$564.88 millionP/E RatioN/ADividend YieldN/APrice Target$15.57 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Editas Medicine MarketRank™ ForecastAnalyst RatingHold2.43 Rating ScoreUpside/Downside125.0% Upside$15.57 Price TargetShort InterestBearish18.60% of Shares Sold ShortDividend StrengthN/ASustainability-0.57Upright™ Environmental ScoreNews Sentiment0.29Based on 11 Articles This WeekInsider TradingSelling Shares$46,111 Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($2.55) to ($2.68) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.93 out of 5 starsMedical Sector709th out of 969 stocksBiological Products, Except Diagnostic Industry114th out of 161 stocks 3.2 Analyst's Opinion Consensus RatingEditas Medicine has received a consensus rating of Hold. The company's average rating score is 2.43, and is based on 7 buy ratings, 6 hold ratings, and 1 sell rating.Price Target Upside/DownsideAccording to analysts' consensus price target of $15.57, Editas Medicine has a forecasted upside of 125.0% from its current price of $6.92.Amount of Analyst CoverageEditas Medicine has only been the subject of 4 research reports in the past 90 days. Previous Next 0.0 Short Interest Percentage of Shares Shorted18.60% of the outstanding shares of Editas Medicine have been sold short.Short Interest Ratio / Days to CoverEditas Medicine has a short interest ratio ("days to cover") of 10.8, which indicates bearish sentiment.Change versus previous monthShort interest in Editas Medicine has recently increased by 4.69%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldEditas Medicine does not currently pay a dividend.Dividend GrowthEditas Medicine does not have a long track record of dividend growth. Previous Next 4.8 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreEditas Medicine has received a 77.02% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Clinical research services for physical health" and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Editas Medicine is -0.57. Previous Next 2.4 News and Social Media Coverage News SentimentEditas Medicine has a news sentiment score of 0.29. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.67 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 11 news articles for Editas Medicine this week, compared to 3 articles on an average week.Search InterestOnly 12 people have searched for EDIT on MarketBeat in the last 30 days. This is a decrease of -59% compared to the previous 30 days.MarketBeat Follows24 people have added Editas Medicine to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Editas Medicine insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $46,111.00 in company stock.Percentage Held by InsidersOnly 2.20% of the stock of Editas Medicine is held by insiders.Percentage Held by Institutions76.61% of the stock of Editas Medicine is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Editas Medicine are expected to decrease in the coming year, from ($2.55) to ($2.68) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Editas Medicine is -2.34, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Editas Medicine is -2.34, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioEditas Medicine has a P/B Ratio of 1.32. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Editas Medicine (NASDAQ:EDIT) StockEditas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis 10; autosomal dominant retinitis pigmentosa; and EDIT-301, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing gene-edited Natural Killer cell medicines to treat solid tumor cancers; alpha-beta T cells for multiple cancers; and gamma delta T cell therapies to treat cancer. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited to discover, develop, and commercialize new gene editing medicines for a range of ocular disorders. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.Read More EDIT Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart EDIT Stock News HeadlinesSeptember 25, 2023 | marketbeat.comAre Gene Therapy Stocks The Market's Next Big Winners? (EDIT)Biotechs Sarepta and BioMarin are among companies advancing cutting-edge gene therapies, although those treatments can come with a $2 million or more price.September 26, 2023 | seekingalpha.comEditas Medicine, Inc. (EDIT) Cantor Global Healthcare Conference 2023 - (Transcript)September 28, 2023 | Behind the Markets (Ad)66,000% upside on tiny biotech?The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.September 25, 2023 | finance.yahoo.comEditas Medicine Strengthens Executive Leadership Team with Appointment of Caren Deardorf as Chief Commercial and Strategy OfficerSeptember 23, 2023 | finance.yahoo.com1 Gene Editing Stock to Buy Now, and 1 to SellSeptember 23, 2023 | americanbankingnews.comZacks Research Weighs in on Editas Medicine, Inc.'s FY2024 Earnings (NASDAQ:EDIT)September 19, 2023 | americanbankingnews.comEditas Medicine (NASDAQ:EDIT) versus Autolus Therapeutics (NASDAQ:AUTL) Critical SurveySeptember 15, 2023 | ca.finance.yahoo.comEditas Medicine, Inc. (EDIT)September 28, 2023 | Behind the Markets (Ad)66,000% upside on tiny biotech?The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.September 11, 2023 | seekingalpha.comEditas Medicine, Inc. (EDIT) CEO Gilmore O'Neill Presents at Morgan Stanley 21st Annual Global Healthcare Conference (Transcript)September 7, 2023 | seekingalpha.comEditas Medicine, Inc. (EDIT) Presents at Wells Fargo Securities Healthcare Conference Call TranscriptSeptember 7, 2023 | finance.yahoo.comLigand (LGND) Down 8.8% Since Last Earnings Report: Can It Rebound?August 30, 2023 | markets.businessinsider.comCantor Fitzgerald Keeps Their Buy Rating on Editas Medicine (EDIT)August 7, 2023 | markets.businessinsider.comTruist Financial Sticks to Their Buy Rating for Editas Medicine (EDIT)August 4, 2023 | markets.businessinsider.comRBC Capital Sticks to Its Hold Rating for Editas Medicine (EDIT)August 3, 2023 | msn.comChardan Capital Maintains Editas Medicine (EDIT) Buy RecommendationJuly 24, 2023 | finance.yahoo.comEditas Medicine Strengthens Executive Leadership Team with Appointment of Linda C. Burkly, Ph.D., as Chief Scientific OfficerJuly 23, 2023 | seekingalpha.comEditas Medicine: Progress, Pitfalls, And Future ExpectationsJuly 17, 2023 | finance.yahoo.comEDIT - Editas Medicine, Inc.July 14, 2023 | msn.comEditas Medicine Bolsters Cash Position Amidst Slow And Steady ProgressJuly 7, 2023 | nasdaq.comEditas Medicine (EDIT) Price Target Increased by 5.56% to 13.68June 26, 2023 | markets.businessinsider.comSVB Securities Sticks to Its Hold Rating for Editas Medicine (EDIT)June 22, 2023 | markets.businessinsider.comRobert W. Baird Remains a Buy on Editas Medicine (EDIT)June 20, 2023 | finance.yahoo.comAfter It Fell 15% in 1 Day, Should You Buy The Dip on Editas Stock?June 16, 2023 | msn.comEditas Medicine down 6%, prices $125M offeringJune 16, 2023 | marketwatch.comEditas Medicine Shares Fall 15% on Pricing of Secondary Stock OfferingJune 16, 2023 | markets.businessinsider.comEditas Medicine Plunges After Pricing 12.5 Mln Share OfferingSee More Headlines Receive EDIT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Editas Medicine and its competitors with MarketBeat's FREE daily newsletter. Email Address EDIT Company Calendar Last Earnings8/02/2023Today9/28/2023Next Earnings (Estimated)11/01/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:EDIT CUSIPN/A CIK1650664 Webwww.editasmedicine.com Phone(617) 401-9000FaxN/AEmployees226Year FoundedN/APrice Target and Rating Average Stock Price Forecast$15.57 High Stock Price Forecast$35.00 Low Stock Price Forecast$7.00 Forecasted Upside/Downside+124.7%Consensus RatingHold Rating Score (0-4)2.38 Research Coverage13 Analysts Profitability EPS (Most Recent Fiscal Year)($2.96) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-220,430,000.00 Net Margins-1,065.39% Pretax Margin-1,065.39% Return on Equity-55.14% Return on Assets-40.13% Debt Debt-to-Equity RatioN/A Current Ratio8.09 Quick Ratio8.09 Sales & Book Value Annual Sales$19.71 million Price / Sales28.70 Cash FlowN/A Price / Cash FlowN/A Book Value$5.25 per share Price / Book1.32Miscellaneous Outstanding Shares81,630,000Free Float79,837,000Market Cap$565.70 million OptionableOptionable Beta1.79 Beginners Guide To Retirement StocksClick the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report Key ExecutivesDr. Gilmore O'Neill (Age 59)Pres, CEO & Director Comp: $815.37kDr. Bruce E. Eaton Ph.D. (Age 69)Exec. VP, CTO & Chief Bus. Officer Comp: $786.23kDr. Baisong Mei M.D.Ph.D., Sr. VP & Chief Medical OfficerDr. Feng Zhang Ph.D.Co-Founder & Scientific Advisory Board MemberDr. George McDonald Church Ph.D. (Age 69)Co-Founder & Scientific Advisory Board Member Dr. J. Keith Joung M.D.Ph.D., Co-Founder & Scientific Advisory Board MemberDr. David R. Liu Ph.D.Co-Founder & Scientific Advisory Board MemberMr. Erick J. Lucera C.F.A. (Age 55)C.P.A., CFA, CPA, CFO & Exec. VP Mr. Harry R. Gill III (Age 62)Sr. VP of Operations Dr. Linda C. Burkly Ph.D.Exec. VP & Chief Scientific OfficerMore ExecutivesKey CompetitorsVectivBioNASDAQ:VECTExscientiaNASDAQ:EXAIAllogene TherapeuticsNASDAQ:ALLOCabaletta BioNASDAQ:CABAAnavex Life SciencesNASDAQ:AVXLView All CompetitorsInsiders & InstitutionsBarclays PLCBought 24,164 shares on 9/21/2023Ownership: 0.367%Bruce EatonSold 103 sharesTotal: $908.46 ($8.82/share)Wolverine Trading LLCBought 11,800 shares on 8/23/2023Ownership: 0.000%California State Teachers Retirement SystemBought 8,743 shares on 8/21/2023Ownership: 0.116%Osaic Holdings Inc.Bought 27,877 shares on 8/21/2023Ownership: 0.085%View All Insider TransactionsView All Institutional Transactions EDIT Stock - Frequently Asked Questions Should I buy or sell Editas Medicine stock right now? 13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Editas Medicine in the last twelve months. There are currently 1 sell rating, 6 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" EDIT shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in EDIT, but not buy additional shares or sell existing shares. View EDIT analyst ratings or view top-rated stocks. What is Editas Medicine's stock price forecast for 2023? 13 brokerages have issued 12 month price targets for Editas Medicine's stock. Their EDIT share price forecasts range from $7.00 to $35.00. On average, they expect the company's stock price to reach $15.57 in the next year. This suggests a possible upside of 124.7% from the stock's current price. View analysts price targets for EDIT or view top-rated stocks among Wall Street analysts. How have EDIT shares performed in 2023? Editas Medicine's stock was trading at $8.87 at the beginning of the year. Since then, EDIT stock has decreased by 21.9% and is now trading at $6.93. View the best growth stocks for 2023 here. When is Editas Medicine's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 1st 2023. View our EDIT earnings forecast. How were Editas Medicine's earnings last quarter? Editas Medicine, Inc. (NASDAQ:EDIT) announced its earnings results on Wednesday, August, 2nd. The company reported ($0.56) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.76) by $0.20. The company had revenue of $2.89 million for the quarter, compared to the consensus estimate of $4.17 million. Editas Medicine had a negative trailing twelve-month return on equity of 55.14% and a negative net margin of 1,065.39%. The firm's revenue for the quarter was down 54.6% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($0.78) EPS. What ETFs hold Editas Medicine's stock? ETFs with the largest weight of Editas Medicine (NASDAQ:EDIT) stock in their portfolio include Kelly CRISPR & Gene Editing Technology ETF (XDNA), iShares Genomics Immunology and Healthcare ETF (IDNA), Horizon Kinetics Medical ETF (MEDX), Direxion Moonshot Innovators ETF (MOON), AXS Green Alpha ETF (NXTE) and WisdomTree BioRevolution Fund (WDNA).Global X Genomics & Biotechnology ETF (GNOM) and What other stocks do shareholders of Editas Medicine own? Based on aggregate information from My MarketBeat watchlists, some companies that other Editas Medicine investors own include CRISPR Therapeutics (CRSP), NVIDIA (NVDA), Micron Technology (MU), Intellia Therapeutics (NTLA), Block (SQ), Advanced Micro Devices (AMD), Alibaba Group (BABA), QUALCOMM (QCOM), Cisco Systems (CSCO) and Skyworks Solutions (SWKS). When did Editas Medicine IPO? (EDIT) raised $100 million in an initial public offering (IPO) on Wednesday, February 3rd 2016. The company issued 5,900,000 shares at $16.00-$18.00 per share. Morgan Stanley and J.P. Morgan acted as the underwriters for the IPO and Cowen and Company and JMP Securities were co-managers. What is Editas Medicine's stock symbol? Editas Medicine trades on the NASDAQ under the ticker symbol "EDIT." Who are Editas Medicine's major shareholders? Editas Medicine's stock is owned by a variety of institutional and retail investors. Top institutional investors include BlackRock Inc. (9.31%), State Street Corp (8.14%), Deep Track Capital LP (4.23%), Marshall Wace LLP (3.48%), Woodline Partners LP (3.37%) and Dimensional Fund Advisors LP (2.16%). Insiders that own company stock include Baisong Mei, Bruce Eaton, Charles Albright, Gilmore Neil O'neill, James C Mullen, Lisa Anne Michaels, Mark S Shearman and Michelle Robertson. View institutional ownership trends. How do I buy shares of Editas Medicine? Shares of EDIT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Editas Medicine's stock price today? One share of EDIT stock can currently be purchased for approximately $6.93. How much money does Editas Medicine make? Editas Medicine (NASDAQ:EDIT) has a market capitalization of $565.70 million and generates $19.71 million in revenue each year. The company earns $-220,430,000.00 in net income (profit) each year or ($2.96) on an earnings per share basis. How many employees does Editas Medicine have? The company employs 226 workers across the globe. How can I contact Editas Medicine? Editas Medicine's mailing address is 11 Hurley Street, Cambridge MA, 02141. The official website for the company is www.editasmedicine.com. The company can be reached via phone at (617) 401-9000 or via email at mark.mullikin@editasmed.com. This page (NASDAQ:EDIT) was last updated on 9/28/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Editas Medicine, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.